Navigation Links
Thoratec Schedules Third Quarter Conference Call, Webcast

PLEASANTON, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in products to treat cardiovascular disease, today announced that it will report its operating results for the third quarter of fiscal 2007 on Thursday, November 1.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 8:30 a.m., Pacific Daylight Time (11:30 a.m., Eastern Daylight Time), Thursday, November 1, hosted by Gary F. Burbach, president and chief executive officer, and David Smith, executive vice president and chief financial officer.

The teleconference can be accessed by calling (913) 312-0946, passcode 4366700. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will also be available on the Internet at or at

A replay of the conference call will be available through Thursday, November 15, via or by telephone at (719) 457-0820, passcode 4366700.

Thoratec Corporation is a world leader in therapies to address advanced stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at or

SOURCE Thoratec Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Shorter Radiation Schedules Found To Be More Effective For Patients With Breast Cancer
2. Vaccination Schedules Rates among Canadian Kids Dip Low
3. UP Government Fixes Work Schedules for Provincial Medical Service Doctors
4. Third artificial heart patient introduced
5. Extra hormone found to cut appetite by a third
6. Third generation Small pox vaccine from Cell-culture
7. Surgery Offers Better Treatment For Third Degree Piles
8. One Third Of All Cancers Preventable!
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Kleins Third Way Has Tough Opposition
11. Ignorance about AIDS rampart in Third of College Students: Chinese survey
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... has announced its acquisition by Jordan Industries International, LLC (“JII”). , With support ... equipment rentals and maintenance services to hospitals, surgery centers, clinics, research labs and ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one ... Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice in ... among the many elite aesthetic physicians honored by the industry publication. , Dr. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: